Poland· PL-100392356
Maviret
A glecaprevir and pibrentasvir product containing glecaprevirum + pibrentasvirum, registered in Poland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 15 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Glecaprevir and pibrentasvir is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AP57 (glecaprevir and pibrentasvir), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Glecaprevir and pibrentasvir · ATC J05AP57
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Glecaprevirum + Pibrentasvirum
- Manufacturer
- AbbVie Deutschland GmbH & Co. KG
- Country
- Poland (PL)
- ATC code
- J05AP57
- ATC class
- Glecaprevir and pibrentasvir
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin08054083015927
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Glecaprevir and pibrentasvir in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaMAVIRETAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- United StatesMavyretAbbVie Inc.
- United KingdomGlecaprevir 100mg / Pibrentasvir 40mg tabletsAbbVie Ltd
- SpainMAVIRET 100 MG/40 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAbbvie Deutschland Gmbh & Co. Kg
- FinlandMaviretAbbVie Deutschland GmbH&Co.KG
- FranceMAVIRET 100 mg/40 mg, comprimé pelliculéABBVIE DEUTSCHLAND (ALLEMAGNE)
- CanadaMAVIRETABBVIE CORPORATION
- IcelandMaviretAbbVie Deutschland GmbH & Co. KG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Glecaprevir/Pibrentasvir Abbvie
- Iceland · Maviret
- Liechtenstein · Maviret
- Norway · Maviret
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e60f9e72-3ce8-4b9a-8706-183fef17c7c3 GET /v1/drugs/e60f9e72-3ce8-4b9a-8706-183fef17c7c3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "100 mg + 40 mg",
"packaging": "08054083015927 ¦ Rpz ¦ EU/1/17/1213/001 ¦ 123942\n84 tabl.",
"substance": "Glecaprevirum 100 mg + Pibrentasvirum 40 mg",
"common_name": "Glecaprevirum + Pibrentasvirum",
"pl_product_id": "100392356",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about glecaprevir and pibrentasvir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.